Method for treating endometriosis or leiomyomata uteri with a competitive progesterone antagonist and a gestagen

2000
OA: closed
⚙ AI-generated summary by qwen3.7-flash, 2026-09-19 ⓘ

A pharmaceutical agent combining sequential oral doses of a non-abortion-inducing competitive progesterone antagonist and a gestagen was developed for treating endometriosis or leiomyomata uteri.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

PCT No. PCT/EP95/02998 Sec. 371 Date Jun. 10, 1997 Sec. 102(e) Date Jun. 10, 1997 PCT Filed Jul. 27, 1995 PCT Pub. No. WO96/03130 PCT Pub. Date Feb. 8, 1996This invention relates to the use of a product that contains in combination individual dosage units of a competitive progesterone antagonist and individual dosage units of a gestagen for its sequential, oral administration, in which each individual dosage unit that contains the competitive progesterone antagonist contains the latter in a non-abortion-inducing amount for the production of a pharmaceutical agent for treating endometriosis or leiomyomata uteri.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-11-22T06:15:05.045840+00:00